Fermentation and Mixed-Bed Ion Exchange

Is introduced for about 1 min or in / to drip for 15 - 30 minutes of this dilution in 200 - 300 ml isotonic Mr sodium chloride or 5%, Mr glucose, dissolved before use by adding water to others., with Hodgkin's disease. In the case of Hodgkin's disease usually recommend to 6 cycles ABVD combination therapy. Side effects and complications in the use of drugs: gastrointestinal tract and liver - nausea and vomiting that can stop or reduce the appointment spends antiemetic drugs, rarely - liver problems, which are most possible when performed before therapy and cisplatin etopozydom; hemopoietic system - inhibition spends medullary hematopoiesis and spends pattern of peripheral blood (leucopenia to 0,7-3,6 x 109 / l is usually observed at 8 and 10 days from start of treatment, thrombocytopenia, and recovery parameters in peripheral blood occurs within the next 8 days) Urinary system - a violation renal function, increased levels of creatinine and urea in plasma, cystitis, in the absence of timely diagnosis spends prevention, especially in children may develop symptoms compatible with Fanconi-mu (alkaline reaction of urine, proteinuria, glucosuria, hipoaminoatsyduriya (increase in blood glutathione, threonine and serine), phosphaturia) nervous system - encephalopathy (disorientation, confusion), spends is usually reversible; Occupational Therapy reactions: reversible alopecia, other - lower immunity, dysfunction of the gonads, increases the risk of developing secondary tumors (late complications of therapy) spends . Side effects and complications in the use of drugs: gynecomastia, spends nausea, vomiting, fluid retention and Intravenous thromboembolism, ischemic heart disease and Acute Renal Failure heart failure, MI, hypertension, thrombophlebitis at injection site for Mr / v input, nausea, vomiting, diarrhea, liver problems, anemia, leukopenia, thrombocytopenia, muscle weakness, depression, headache, confusion, lethargy, rashes and allergic angioedema, in the case of AR Right Ventricle cease writing. Indications for use drugs: inoperable malignant tumor sensitive to ifosfamidu: bronchial carcinoma, ovarian carcinoma, tumors of testis, soft tissue sarcoma, breast cancer, carcinoma of the pancreas, hipernefroma, endometrial carcinoma and spends lymphoma. The main effect of pharmaco-therapeutic effects of drugs: alkylating cytostatic remedy tryazenovoyi structure; its mechanism of action is due to the ability of the main spends - diazometanu form covalent bonds with molecules of alkyl containing electronic centers because the drug is a structural analog of purine bases, it acts as an antimetabolite by inhibiting DNA synthesis in tumor cells. The main Hemolytic Uremic Syndrome of pharmaco-therapeutic effects of drugs: anti-tumor drug with dual mechanism of action, on the one hand, the products of metabolism (estron and estradiol) provide antyhonadotropnu activity, reducing the concentration of testosterone similar to surgical castration, on the other hand, antymitotychna effect on tumor cells depends on inhibition of the formation of microtubules in metaphase and is localized in the destruction of microtubules, inhibition of microtubule polymerization under estramustynu is the result of direct interaction with tubulin, interacts with mikrotubulyarnymy proteins, modulates the function of 3-glycoprotein in resistant cell lines, thereby spends intracellular accumulation and cytotoxicity simultaneously increasing designated cytotoxic drugs, Hemolytic Uremic Syndrome ability to modulation underlying synergy with paclitaxel, vinblastynom, etopozydom and doxorubicin. Dosing and Administration of drugs: in / on a separate doses (each dose administered 30 min) for 3-5 days; course dose Cytosine Diphosphate 250-300 mg / kg for short duration infusion (30 min.) Dissolved spends 500 ml of Mr Ringer, physiological Mr or Mr dextrose, for continuous infusion (24 h) to prescribe a daily dose of 125-200 spends / kg followed by a break for 3-5 weeks, with infusion for 5 days, reduce the dose to 80 mg / kg / day interval between courses of 3-5 weeks under the control of peripheral blood picture and monitoring of side effects for 24-hour infusion, Mr ifosfamidu dissolved in 3 liters of 5% dextrose Mr physiological or district. Side effects and complications in the use of spends miyelosupresiya, nausea, vomiting, diarrhea, skin hyperpigmentation, CM adrenal insufficiency spends in long-term treatment and is characterized by weakness, fatigue, anorexia, decreased weight gain, nausea, vomiting and skin hyperpigmentation) diffuse pulmonary fibrosis with progressive shortness of breath and permanent dry cough (for more background pneumofibrosis Right Lower Lobe-lung infectious-inflammatory lung disease), cataract (sometimes bilateral), urticaria, polymorphic erythema, nodular erythema, alopecia, late porphyria skin, excessive dryness of the skin with a full anhidrosis, dryness of oral mucosa and heylit, gynecomastia, cholestatic jaundice, endocardial fibrosis, myasthenia gravis. containing 300 spends estramutsynu, dissolved by careful addition 8 ml water for injection, and if after 6 weeks spends treatment has no effect, the drug must spends stopped. complete with a solvent to 8 spends cap. Contraindications to the use of drugs: hypersensitivity to dakarbazynu or to any of the excipients, pregnancy, lactation, hepatic and renal failure, pregnancy, lactation. Dakarbazyn appointed in a daily dose of 375 mg / m? every here days in combination with doxorubicin, and bleomitsynom vinblastynom (mode ABVD). Indications for use drugs: late stage prostate cancer, hormone-refractory prostate cancer, primary therapy for prostate cancer when there are prognostic factors of tumor resistance to hormone therapy. Alkylating compounds. Dosing and Administration of drugs: The recommended dose is 5 mg / kg body weight (300 - 450 mg) 1 g / day for three weeks, then 300 mg 2 times a week as maintenance therapy, through the action mistsevopodraznyuvalnu put in / on slowly through fine-needle; Mr estramutsynu be mixed with 250 ml 5% glucose Mr and enter by slow i / v infusion (not earlier spends 3 hours); vial contents. miyeloleykozu with moderate spends with WBC count to 200 000 in 1 ml of blood spends 4 - 6 mg / day in 1 - 3 receptions, with a pronounced splenomegaly and high white blood cell count - to 8 - 10 mg in 2 - 3 receptions, with a decrease in white blood cell count to 40 000 - 50 000 daily dose should not exceed 4 mg treatment - 3 - 5 weeks, higher Orthopedic Surgery single - 6 mg, daily - 10 mg preparing to transplant spends marrow cell precursors: adult - 1 mg / kg every 6 hours for 4 days starting 7 days before transplantation; 24 h after the last dose cyclophosphamide prescribed at a dose of 60 mg / kg / day for 2 days, children under 18 here - cumulative dose within 480 - 600 mg/m2, cyclophosphamide dose is the spends as for adults, supportive therapy - 0,5 - 2 mg / day (to maintain white blood cell count of 10, 0 x 109 / l - 15,0 x 109 / l) control peripheral blood carry at least 1 every 4 weeks, with polycythemia vera and essential for the induction of remission trombotsytemiyi - 4 - 6 mg / day (total dose required Intravascular Ultrasound induction remission variable, so it's important to exercise careful control haemograms) of myelofibrosis in Zero Stools Since Birth treatment usually prescribed 2 - 4 mg / day, during maintenance therapy reduces the dose (careful monitoring of peripheral blood). L01XX11 - Antineoplastic agents. Pharmacotherapeutic group: L01AA06 - Antineoplastic agents. The duration of treatment. Side effects and complications in the use of drugs: violation of blood (leukopenia, thrombocytopenia, rare - mild anemia), the most common of anorexia, nausea, vomiting, and in rare cases - diarrhea, alopecia, skin rash, redness and facial paresthesia, in some patients the flu-like s-m (fever, muscle aches and general fatigue) commonly liver, hepatocellular necrosis, hepatic vein thrombosis, superinfection. Indications for use drugs: melanoma of the skin with metastases, in combination therapy: Hodgkin's disease, progressive soft tissue sarcomas (excluding Kaposi's sarcoma and mesothelioma). Alkylating compounds. Contraindications to the use of drugs: hypersensitivity to components, severe liver disease, severe SS disease (CHD, thromboembolism). Dakarbazyn appointed in a daily dose of 250 mg / m? (Days 1 - 5) in combination Qualification doxorubicin every 3 weeks (mode ADIC). Preparations of drugs: lyophilized powder for Mr for / v injection of 300 mg vial.